Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Acella Pharmaceuticals, LLC
WARNING LETTER
•Acella Pharmaceuticals, LLC•January 7, 2020

Acella Pharmaceuticals, LLC – FDA Warning Letter, Jan 7, 2020

Record Details

The FDA inspected Acella Pharmaceuticals, LLC (FEI 3006691461) from December 17, 2019, to January 7, 2020, identifying significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). This renders their drug product adulterated under section 501(a)(2)(B) of the FD&C Act. Additionally, NP Thyroid products are adulterated under section 501(b) for failing to conform to compendial standards for strength, quality, or purity. NP Thyroid products are also considered unapproved biological products.

Violations include: 1. **Failure to establish adequate laboratory controls (21 CFR 211.160(b))**: Acella's active ingredient assay specifications for levothyroxine and liothyronine in NP Thyroid were (b)(4), while the USP monograph for Thyroid Tablets requires (b)(4). Although Acella updated specifications, an FDA inspection of their CMO (May 5-15, 2020) found 13 lots within expiry, made with a previous API supplier, that exceeded 110.0% USP specification during release or stability testing, which Acella subsequently recalled. 2. **Failure to establish an adequate quality control unit (21

Company
Acella Pharmaceuticals, LLC
Inspection date
January 7, 2020
Product type
Drugs
Office
Office of Pharmaceutical Quality Operations Division I
Person
  • Tamala P. Bogan (Director of Investigations Branch)
View Company Profile

ID · 65e0ddf5-ebd7-4a30-9f88-ce5bdb9a6402

Violation Codes10
21 U.S.C. 321(g)21 CFR 21021 CFR 21121 CFR 211.160(b)21 CFR 211.22(a)FD&C Act 501(a)(2)(B)FD&C Act 501(b)21 U.S.C. 351(b)FD&C Act 201(g)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Acella Pharmaceuticals, LLC
  • 483 - 2024-12-18December 18, 2024
  • 483 - 2023-02-10February 10, 2023
  • 483 - 2021-09-17September 17, 2021
  • EIR - 2020-01-07January 7, 2020
  • 483 - 2020-01-07January 7, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Acella Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.